Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monoclonal gammopathy of undetermined significance: a consensus statement.
Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. Berenson JR, et al. Among authors: yellin o. Br J Haematol. 2010 Jul;150(1):28-38. doi: 10.1111/j.1365-2141.2010.08207.x. Epub 2010 May 9. Br J Haematol. 2010. PMID: 20507313 Free article.
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH, Upadhyaya GH, Flinn IW, Staszewski H, Tiffany NM, Sanani S, Farber CM, Morganstein N, Bolejack V, Nassir Y, Hilger JD, Sefaradi A, Shamouelian A, Swift RA. Berenson JR, et al. Among authors: yellin o. Am J Hematol. 2011 Jan;86(1):25-30. doi: 10.1002/ajh.21912. Am J Hematol. 2011. PMID: 21120861 Free article.
A retrospective study to evaluate the work-up and follow-up of patients with monoclonal gammopathy of undetermined significance.
Berenson JR, Yellin O, Quiery A, Brady J, Patel R, Wong SF, Colbourn D, Gravenor D, Tiffany N, Shamasunder HK, Waterman B, Melamed K, Wirtschafter E. Berenson JR, et al. Among authors: yellin o. Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):336-41. doi: 10.1016/j.clml.2011.02.002. Epub 2011 May 6. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21816371
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, Wilson J, Yellin O, Morrison B, Hilger J, Swift R. Berenson JR, et al. Among authors: yellin o. Ann Hematol. 2008 Aug;87(8):623-31. doi: 10.1007/s00277-008-0501-0. Epub 2008 May 8. Ann Hematol. 2008. PMID: 18463870 Clinical Trial.
New drugs in multiple myeloma.
Berenson JR, Yellin O. Berenson JR, et al. Among authors: yellin o. Curr Opin Support Palliat Care. 2008 Sep;2(3):204-10. doi: 10.1097/SPC.0b013e3283090475. Curr Opin Support Palliat Care. 2008. PMID: 18685422 Review.
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, Eades B, Abaya CD, Hilger J, Swift RA. Berenson JR, et al. Among authors: yellin o. Eur J Haematol. 2009 Jun;82(6):433-9. doi: 10.1111/j.1600-0609.2009.01244.x. Epub 2009 Feb 17. Eur J Haematol. 2009. PMID: 19226361 Clinical Trial.
27 results